Showing 1701-1710 of 2054 results for "".
- Adverum Initiates ARTEMIS Phase 3 Study to Evaluate Ixo-vec for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-initiates-artemis-phase-3-study-to-evaluate-ixo-vec-for-wet-amd/2482686/Adverum Biotechnologies announced the initiation of ARTEMIS phase 3 study to evaluate Ixo-vec gene therapy (ixoberogene soroparvovec) as a one-time intravitreal (IVT) injection for neovascular (wet) age-related macular degeneration (AMD). Wet AMD is a leading cause of blindness in the e
- Altris AI Launches Advanced Optic Disc Analysis for Glaucomahttps://modernod.com/news/altris-ai-launches-advanced-optic-disc-analysis-for-glaucoma-complementing-gcc-asymmetry-analysis/2482683/Altris AI, a provider of AI OCT scan analysis for the detection of a range of retina pathologies and biomarkers, announced the launch of an advanced glaucoma 'Optic Disc Analysis' module. To address need to improve timely and accurate gl
- Dry Eye Institute Launches 'DEI On Demand' and Kicks Off Inaugural Road Eventhttps://modernod.com/news/dry-eye-institute-launches-dei-on-demand-and-kicks-off-inaugural-road-event/2482605/The Dry Eye Institute (DEI), an educational program for optometrists and ophthalmologists specializing in advanced dry eye care, has announced that for the first time, the institute’s curriculum is now available online through 'DEI On Demand.' DEI also announced that
- Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2https://modernod.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2/2482531/Neurotech Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date by 3 months to allow time required for the FDA to review additional data provided by the company in response to recent requests from the FDA. Originally set for December 17
- Centricity Vision Unveils Enhancements to ZEPTOLink IOL Positioning System at AAO 2024https://modernod.com/news/centricity-vision-unveils-enhancements-to-zeptolink-iol-positioning-system-at-aao-2024/2482487/Centricity Vision announced platform enhancements for its ZEPTOLink IOL Positioning System designed to reduce treatment time by up to 60%. The enhancements will be highlighted at the American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21, 2024, in Chicago.
- RetinaLyze Launches Advanced Glaucoma Progression AIhttps://modernod.com/news/retinalyze-launches-advanced-glaucoma-progression-ai/2482480/RetinaLyze has introduced the Advanced Glaucoma Progression AI. Central to this technology is the 'Glaucoma Index of Progression' (GIP), a tool designed to provide a stable and consistent method for tracking glaucoma progression over time. Glaucoma, often referred to a
- Topcon Receives FDA Clearance for OCT Angiography on the Maestro2 Systemhttps://modernod.com/news/topcon-receives-fda-clearance-for-octa-on-the-maestro2-system/2482439/Topcon Healthcare has received FDA 510(k) clearance for OCT angiography (OCTA) on the company’s Maestro2 robotic OCT color fundus camera system. According to Topcon, the Maestro2 offers 3×3-mm, 4.5×4.5-mm, and 6x6-mm OCTA scans, which provide the flexibility to le
- Heidelberg Engineering Introduces Faster OCT Angiography with Spectralis Shift Technologyhttps://modernod.com/news/heidelberg-engineering-introduces-faster-oct-angiography-with-spectralis-shift-technology/2482359/Heidelberg Engineering has received FDA clearance of the Spectralis OCTA Module with Shift technology, which is designed to reduce acquisition time by 50%.[1] The preset OCTA speed of 125 kHz helps streamline workflow, enhance clinical e
- Geoff Tabin, MD, Co-Founder of Global NGO HCP Cureblindness, Steps Into New Rolehttps://modernod.com/news/geoff-tabin-md-co-founder-of-global-ngo-hcp-cureblindness-steps-into-new-role/2482314/Effective immediately, Geoff Tabin, MD, will step down as Board Chair of the global nonprofit HCP Cureblindness (Himalayan Cataract Project), but will maintain an active role on the Board as Medical Director. Long-time HCP volunteer and Board Member, Matt Oliva, MD, will lead HCP into its excitin
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par